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Accepted 25 March 2013On April 10, 2010 the Institutes of Medicine (IOM)
released its report, A National Cancer Clinical Trials System
for the 21st Century: Reinvigorating the NCI Cooperative
Group Program. The IOM report called for major efforts to
improve the speed and efﬁciency of design, launch, and
conduct of cancer clinical trials; to make optimal use of
scientiﬁc innovations; to improve the selection, prioritiza-
tion, support, and completion of trials; and to foster
expanded participation of both patients and physicians [1].
Almost 2 years later, in the May 10 issue of New England
Journal of Medicine, 2 original articles describing the
beneﬁcial effect of continuous lenalidomide therapy after
autologous hematopoietic stem cell transplantation (HCT)
for multiple myeloma were published [2,3]. These articles
were cited as demonstrating major advances in cancer
treatment in 2012 by the American Society of Clinical
Oncology in its annual Report on Progress Against Cancer [4].
One of these articles [2] was noteworthy not only for its
potentially practice-changing ﬁndings but also because it
was the product of a rigorously conducted, large, cooperative
group study performed in the United States.
The other study [3] was a product of the Intergroupe
Francophone du Myelome, based in France, which has
completed at least 5 deﬁnitive trials of HCT in myeloma since
1996. During that time, only 1 large cooperative group study
of HCT for myeloma was completed in the United States.
However, this paucity of US HCT trials seems to be changing.
In 2011, the Blood andMarrow Transplantation Clinical Trials
Network (BMT CTN) 0102 study was published [5]. BMT CTNFinancial disclosure: See Acknowledgments on page 859.
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http://dx.doi.org/10.1016/j.bbmt.2013.03.0150102 enrolled 710 patients from 37 centers over 3 years to
compare an allogeneic versus a second autologous HCT after
autologous HCT done as consolidation therapy for the initial
treatment of myeloma. It found no signiﬁcant advantage for
allogeneic HCT in patients with standard-risk disease, which
is in itself an important observation, but the study also
demonstrated that large multicenter HCT trials can be
successfully performed in North America.
The BMT CTN was established in 2001 to “conduct
scientiﬁcally meritorious multicenter trials in an efﬁcient
manner to improve transplantation outcomes.” It is funded
by the National Heart, Lung, and Blood Institute and the
National Cancer Institute (NCI) and has enrolled more than
4800 patients to 25 trials since 2003. It provides an impor-
tant infrastructure to design, implement, and complete
multicenter HCT trials in the United States. Although com-
posed of 20 core centers and/or consortia, other US centers
may access trials as afﬁliate centers through a simple appli-
cation process.
As accrual to BMT CTN 0102 neared completion, and
realizing the importance of national collaboration in the
success of that trial’s accrual, the BMT CTN convened several
meetings of experts in the US myeloma HCT community to
consider a successor trial. These meetings included re-
presentatives from the BMT CTN and the NCI-funded co-
operative trial groups. The ﬁrst meeting of this Myeloma
BMT CTN-Intergroup Committee was in Minneapolis in
November 2006. Therewas consensus that successful accrual
to multicenter trials required active collaboration to priori-
tize the questions of interest and coordination to avoid
competing trials. The group also agreed that after accrual to
BMT CTN 0102 was complete, the BMT CTN would endorse
and help complete accrual to the ongoing but, at that time,
slowly accruing Cancer and Leukemia Group B (CALGB)
100104 study, which was evaluating the use of lenalidomide
maintenance therapy after HCT [2]. BMT CTN centers afﬁli-
ated with CALGB or the Eastern Cooperative Oncology Group
were encouraged to activate the trial through their cooper-
ative group. An amendment was then added to allow another
5 BMT CTN centers to access the trial though the ClinicalTransplantation.
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Figure 1. Monthly and cumulative accrual to Cancer and Leukemia Group B 100104. The star indicates the date that Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) ofﬁcially endorsed the trial and began intensive efforts at boosting accrual.
S. Giralt et al. / Biol Blood Marrow Transplant 19 (2013) 858e859 859Trials Support Unit. Immediately after the BMT CTN
endorsement, more than 20 additional centers activated the
trial with minimal delay. At the end of 2006, only 17 centers
had enrolled patients on this trial; by the end of 2007, 30 had
enrolled patients and by the end of 2009, 46 had enrolled
patients. The BMT CTN Data and Coordinating Center, in
collaboration with the Myeloma BMT CTN-Intergroup
Committee, initiated an intensive accrual effort, including
webcasts, video presentation, e-mail broadcasts, informa-
tional materials, and a series of presentations at national
meetings. The effect of these efforts on enrollment is shown
in Figure 1, which illustrates accrual before and after May
2007, when BMT CTN ofﬁcially endorsed the trial and
implemented its accrual plan.
The trial completed accrual in 2009 and the results,
published in New England Journal of Medicine [2], showed
a survival advantage and a dramatic improvement in
progression-free survival with use of maintenance therapy
with lenalidomide compared with controls. This achieve-
ment was only possible with full support, not only from
investigators in dozens of centers, but also from staff at the
National Heart, Lung, and Blood Institute, NCI, the BMT CTN
Data and Coordinating Center, and the Clinical Trials Support
Unit. CALGB 100104 was truly a cooperative group effort
involving multiple centers, multiple networks, and multiple
institutes. This aspect of its successful completion is as
important as any of the other “Methods” employed in its
implementation and described in the manuscript.
The collaborative efforts that began with the ﬁrst BMT
CTN myeloma trial and continued with CALGB 100104 also
resulted in the design and implementation of BMT CTN 0702
(the STaMINA trial), which explores the role of 3 different
consolidation strategies in myeloma. BMT CTN 0702 has
been endorsed by Eastern Cooperative Oncology Group, the
Southwest Oncology Group (now SWOG), and CALGB (now
the Alliance). This trial opened in June 2010 and has already
accrued 469 patients (70 ahead of predicted) and is expected
to reach its target of 750 patients by December 2013.
Our experience demonstrates that the recommendations
of the IOM can be realized as long as our commitment to
collaboration continues. The Myeloma BMT CTN-IntergroupCommittee will meet this fall to prepare a follow-up study
for BMT CTN 0702. Many questions remain to be addressed:
Is there a better conditioning regimen than melphalan
200 mg/m2? What is the optimal duration of lenalidomide
maintenance after transplantation? Will the addition of new
agents, such as elotuzumab, oral proteasome inhibitors, or
bortezomib, to post-transplantation lenalidomide result in
better disease control? Our experience with CALGB 100104
tells us that these questions can be answered in a timely
manner only if we truly work together and collaboratively
select, design, and implement the critical trials needed to
improve patient outcomes.ACKNOWLEDGMENTS
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